Pharmaceutical stocks continue to assert a comparatively steady influence on a correcting market. They held four of 16 slots among Stock Spotlight issues on Monday, two biotechs and two makers of generic drugs. Chart-wise, Akorn Pharmaceuticals (AKRX) and Gilead Sciences (GILD) have behaved best. Actavis (ACT) has delivered its share of drama. But in terms of suspense, orphan-drug pioneer Alexion Pharmaceuticals (ALXN) is the star.